Skip to main content

Table 1 Characteristics of the included studies

From: Prognostic value of TGF-β in lung cancer: systematic review and meta-analysis

Study Year Country Ethnicity Design NOS score Sample PE NE Gender (M/F) Age (years) Method Stage ADC SCC Others Treatment Follw-up(months)
Hasegawa et al. 2001 Japan Asian ROS 7 53 27/26 64 ELISA I-IV 33 19 1 surgery 41(6–74)
Huang et al. 2014 China Asian ROS 8 194 99 95 138/56 FFPE I-IV 107 76 11 surgery 60(5–72)
Kumar et al. 2011 India Asian ROS 8 42 55.5 ELISA I-IV CT 27.6(14–72)
Kumar et al. 2010 India Asian ROS 7 100 92/8 56 ELISA III-IV 23 77 0 surgery+CT + RT 27(24–30)
Takanami et al. 1994 Japan Asian ROS 7 88 39 49 50/38 61 ELISA I-IV 88 0 0 surgery
Takanami et al. 1997 Japan Asian ROS 7 120 66 54 ELISA I-IV 120 0 0 surgery 84(60–144)
Xie et al. 2015 China Asian ROS 8 85 48 37 61/24 60 ELISA I-IV 47 28 10 surgery+CT + RT 36(4–74)
Zhao et al. 2010 China Asian ROS 8 65 59 ELISA III 19 42 4 CT + RT
  1. ROS Review observational study, FFPE Formalin-Fixed and Parrffin-Embedded, ELISA Enzyme-linked immuno sorbent assay, SCC squamous cell carcinoma, ADC Adenocarcinoma, RT Radiation therapy, CT Chemotherapy, PE Postive expression, NE Negative expression